The FDA has approved nivolumab plus platinum-doublet chemotherapy for patients with non-small cell lung cancer in the neoadjuvant setting. Nivolumab is the first immune checkpoint inhibitor to get approval for resectable NSCLC….
Tag: Lung Cancer Drugs
European Commission Approves Pfizer’s Lorviqua for Advanced Lung Cancer Treatment
European Commission (EC) has granted marketing authorization for Lorviqua as monotherapy for treatment of patients with anaplastic lymphoma kinase (ALK) – positive advanced non-small cell lung cancer. Lorviqua is approved in US…
US FDA Approves Roche’s Tecentriq as Adjuvant Treatment for Early NSCLC
The US Food and Drug Administration (FDA) has approved Roche’s Tecentriq or atezolizumab as adjuvant treatment for patients with Stage II-IIIA non-small cell lung cancer (NSCLC) whose tumors express PD-L1=1%, as determined…
Combination of Experimental Drugs Shown to Extend Lung Cancer Survival in Mice
According to a new study led by researchers at NYU Grossman School of Medicine and its Laura and Isaac Perlmutter Cancer Center, a combination of experimental drugs has shown to extend survival…
FDA Approves First Targeted Therapy for Lung Cancer with Specific Genetic Mutation
The U.S. Food and Drug Administration has approved Lumakras (sotorasib) as first treatment for non-small cell lung cancer patients whose tumors have specific type of genetic mutation called KRAS G12C. It is…
Topotecan–Berzosertib Combination Effective for SCLC Treatment
Researchers all over the world are continuously been working towards finding effective treatments and therapies for lung cancer. There are widely two types of lung cancer: small cell lung cancer (SCLC) and…
FDA Approves Libtayo as Monotherapy for Advanced NSCLC
Lung cancer is one of the leading causes of cancer-related deaths worldwide. In the year 2020, an estimated 225,000 new cases were diagnosed in the United States. Also, approximately 84% of all…
New Study Identifies Drug to Boost Lung Cancer Survival Rates
A new study has found that a newly approved drug for leading form of cancer, lung cancer works to improve patient survival rate. The immunotherapy drug is called Tecentriq or atezolizumab. It…